Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells - Wikidata - awgldk - TriplyDB

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

http://www.wikidata.org/entity/Q42156460

about

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor Novel agents for multiple myeloma to overcome resistance in phase III clinical trials New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Novel therapeutic strategies for multiple myeloma Aggresome formation and neurodegenerative diseases: therapeutic implications microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells Targeting the UPS as therapy in multiple myeloma.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.Panobinostat in lymphoid and myeloid malignancies.A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.Deacetylase inhibitors: an advance in myeloma therapy?Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.Novel approaches to treatment of double-refractory multiple myeloma.The DAC system and associations with multiple myeloma.Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Proteasome inhibitors in the treatment of multiple myeloma In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells The use of novel agents in the treatment of relapsed and refractory multiple myeloma MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101

P2860

Q26739689-8C461289-E836-42A0-8719-9D57ADF3427B Q26745930-9DE646D4-5B26-4F96-A3C1-E0388D40F4D0 Q26747768-32590FB2-EA92-4532-8C7B-5570B799B103 Q26822754-CCE13AA4-D768-402E-92D9-F1D6AB26DB2E Q27004421-481B3CE0-222F-4E00-87CE-FF5A82AF3970 Q27024076-F05D67D5-3E73-4EDC-A0E7-8AAE555F7AD0 Q28069789-B44AC3D1-5BFA-4011-ABDA-DAF1BB9A87DF Q28081590-DFB88B87-5418-44DC-A4E7-4B07334B3284 Q28265926-4380CB03-9E0A-40C5-94E8-62165740480F Q28284121-96F7B1C8-C702-4858-BEB5-B71687165BED Q28481321-EBD12623-C613-4A11-8CC4-789ACCC6CDB9 Q33384287-45512156-BEAA-4FB7-BC8E-A65FC7F360D6 Q33390876-499DED4C-B1A2-4C30-990F-68138DB7CA27 Q33392081-FEEF6B02-7E9D-4FBF-8698-45E66D4A1B3A Q33398014-C0E911CC-580E-4A93-A2A6-931EE9372845 Q33399706-C51BD795-6A3D-4350-AE04-C49CD338E148 Q33400014-029DB18C-4BBB-4733-B900-4B6BFC10C1B9 Q33405714-EAB517B4-61E8-4207-B256-430B99EB73B0 Q33408889-7A6C58C4-249B-493A-89FF-32205D338E37 Q33410997-80BC99A4-FF98-485C-965E-58F3249CE653 Q33436890-E01B7112-4115-454B-899E-034E9FC84190 Q33438321-45D7FB63-1CE3-4F5B-8242-5B680663D78E Q33443001-B29B0A20-7E30-46B1-9255-EB5A5360BD9B Q33443417-8647A0E1-9611-44A2-A44B-B1FA82C6BA6A Q33896749-CA841282-BDAD-4AE4-B751-A0CA9A269321 Q33983255-6148B3BA-039F-4008-9117-0C1975B8FACB Q34134986-452BCF46-E4BE-4D5E-8382-A48A3D30BEB8 Q34168461-EC7B9D8A-6763-4144-9832-BED2B8DF2096 Q34194704-B5A08592-4E48-4FE5-986B-45A76EBEAED8 Q34224278-A3195331-D231-4E14-8C65-96714DE13609 Q34227679-E8C8FFA2-D98B-4B4D-B7B6-3E2A6C581A09 Q34347172-33586797-E045-40FE-88C5-CDD63EF8D453 Q34414447-68DF5BD1-E155-4096-903D-4060FDFFEFF2 Q34441748-C72F6120-4859-48DA-A5AE-0064A14F5C0D Q34602263-9140A9B6-A19D-4457-BDAF-542E7B567989 Q34611676-893E0DC2-2A3F-43BE-B376-4F415D953C94 Q35007061-449FBA36-F547-472C-9BED-47B47B803C14 Q35097319-D3036EAE-B11C-406C-AADF-544D796041D0 Q35178969-E4CD1F55-02D1-4C49-9791-062B3434F958 Q35251058-C70B95E6-215B-44B0-86AC-033CD2FB63B4

P2860

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

http://www.wikidata.org/entity/Q42156460

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Aggresome induction by proteas ...... e synergistic in myeloma cells

@en

Aggresome induction by proteas ...... ylation by tubulin deacetylase

@nl

type

label

Aggresome induction by proteas ...... e synergistic in myeloma cells

@en

Aggresome induction by proteas ...... ylation by tubulin deacetylase

@nl

prefLabel

Aggresome induction by proteas ...... e synergistic in myeloma cells

@en

Aggresome induction by proteas ...... ylation by tubulin deacetylase

@nl

P1433

Q42156460-1CE4667B-DA1C-4E7A-9422-91AB878E2557

P1476

Q42156460-98292B80-1CD2-42DA-9979-68AAEBE41223

P2093

Q42156460-2CCA155D-6FBF-41DD-9610-2DE9435D3CF5

Q42156460-348306E4-9972-4BA8-A03D-49B87412FFA0

Q42156460-3C0367F6-1ECB-47DB-B281-A5BB7F4547FC

Q42156460-4C2E7936-73F1-4ED8-804B-7A6192524EB8

Q42156460-68EAA373-E318-4775-8D1A-C93280351A06

Q42156460-78D4CB52-E9D7-497B-B953-7D6D0C8FD74B

Q42156460-99F95795-1985-45B2-94E0-A6BCF9EE0AC8

Q42156460-BFDB6AFF-B4A1-41FE-A0B1-9604600584F4

Q42156460-D6DD50B6-8F31-42DE-A28D-4A40D8E31421

Q42156460-DDB75B29-2255-4F88-BB1E-2A5ADD86FFF4

P2860

Q42156460-032F58DB-B3D5-491F-A8D4-993A20563DEC

Q42156460-07ED9A19-925B-4895-B583-DF35BFD4243A

Q42156460-177FD9F6-9FA1-4ABC-A066-23B226BE2468

Q42156460-1BA39BDA-4EEF-4E68-8728-4A5C4BC7E6D9

Q42156460-24FEF531-B212-409A-BB7C-9015D0B4C8FC

Q42156460-27990E5A-1914-4B0D-B9E8-BDAE1FFE014C

Q42156460-2BA8834D-2FAC-4834-B3B4-61D53B44A6FC

Q42156460-341E8895-D66A-4F12-8E4C-6BE4B384E709

Q42156460-35360852-414E-4D0B-9949-E791D6D2346A

Q42156460-3BE9DBEF-D67A-4CB4-A6ED-7A96F6CF5486

P304

Q42156460-301C406B-0D81-4691-9937-6D202768150A

P31

Q42156460-15B7C2AD-B2CE-4A8E-A22A-1312C04ED3CA

P356

Q42156460-5F9EEDBC-7E1F-4981-8D78-DE1401BD44FE

P407

Q42156460-DFBFF37A-5E8B-4D3F-B50B-8C3095391345

P433

Q42156460-22EC3B04-9C68-42D1-BCC0-26F1C49028E2

P478

Q42156460-D66F24E6-A86C-4AC5-8A72-2B61849AB958

P50

Q42156460-506DEA22-4369-4177-B243-4E9A008C8EAE

P577

Q42156460-40019F8C-BA70-427D-A12B-EA43A7DEA5CD

P5875

Q42156460-C1F6960F-B6EB-4CE8-8351-B3602C64D7CE

P698

Q42156460-AB3433A1-0ADD-4B70-905B-3035F8A6E536

P932

Q42156460-5EC8F1D8-DA62-4AD8-8EF6-DECC1F6367A7

P356

BLOOD-2006-04-016055

P1433

P1476

Aggresome induction by proteas ...... e synergistic in myeloma cells

@en

P2093

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Ellen Weisberg

http://www.w3.org/2001/XMLSchema#string

Laurence Catley

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Paola Neri

http://www.w3.org/2001/XMLSchema#string

Peter Atadja

http://www.w3.org/2001/XMLSchema#string

Pierfrancesco Tassone

http://www.w3.org/2001/XMLSchema#string

Tanyel Kiziltepe

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

Yu-Tzu Tai

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of a histone deacetylase, HDAC9

Molecular cloning and characterization of a novel histone deacetylase HDAC10

HDAC6 is a microtubule-associated deacetylase

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

Structure and functions of the 20S and 26S proteasomes

Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

Aggresomes: a cellular response to misfolded proteins

XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response

P304

3441-3449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-04-016055

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

P577

2006-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7053428

http://www.w3.org/2001/XMLSchema#string

P698

16728695

http://www.w3.org/2001/XMLSchema#string

P932

1895432

http://www.w3.org/2001/XMLSchema#string